StockNews.AI

Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

StockNews.AI • 1 minute

XYZABCDEF
High Materiality8/10

Information

DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) --  Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer an...

Original source

AI Summary

Arcadia Biosciences is exercising outstanding investment options at a lower price. The reduced exercise price is $2.575, a substantial decrease from $9.00. Gross proceeds from the offering are estimated at $2.1 million. New preferred investment options for 1.6 million shares will be issued at $2.325. Proceeds will be used for working capital and corporate purposes.

Sentiment Rationale

The substantial exercise of investment options indicates confidence in future growth. Historical examples show similar funding rounds bolstering stock prices.

Trading Thesis

Immediate capital influx is likely to boost investor confidence, affecting short-term price positively. However, long-term effects depend on operational performance.

Market-Moving

  • Arcadia Biosciences is exercising outstanding investment options at a lower price.
  • The reduced exercise price is $2.575, a substantial decrease from $9.00.
  • Gross proceeds from the offering are estimated at $2.1 million.

Key Facts

  • Arcadia Biosciences is exercising outstanding investment options at a lower price.
  • The reduced exercise price is $2.575, a substantial decrease from $9.00.
  • Gross proceeds from the offering are estimated at $2.1 million.
  • New preferred investment options for 1.6 million shares will be issued at $2.325.
  • Proceeds will be used for working capital and corporate purposes.

Companies Mentioned

  • XYZ (XYZ)
  • ABC (ABC)
  • DEF (DEF)

Corporate Developments

The significant capital raise reveals strong investor interest, impacting market perception positively.

Arcadia Biosciences (RKDA) Announces $2.1 Million from Preferred Investment Options

DALLAS, January 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc. (Nasdaq: RKDA) has announced the immediate exercise of certain preferred investment options, generating gross proceeds of approximately $2.1 million. This transaction is expected to strengthen the company's financial position and support its ongoing corporate needs.

Details of the Investment Transaction

Arcadia Biosciences has entered into definitive agreements to exercise 808,595 outstanding preferred investment options that were originally issued in December 2020, January 2021, August 2022, and March 2023. The options will be exercised at a reduced price of $2.575 per share, compared to the original exercise price of $9.00 per share.

The common stock resulting from this exercise is registered under effective registration statements on Form S-1 and Form S-3. This allows for smoother processing as part of the transaction.

Use of Proceeds and Future Options

The gross proceeds from the exercise of these options will be allocated towards working capital and general corporate purposes, enhancing Arcadia's operational flexibility.

In return for the immediate cash exercise, Arcadia will issue new unregistered preferred investment options to purchase an additional 1,617,190 shares of common stock at an exercise price of $2.325 per share. These new options will be immediately exercisable and valid for 30 months following the effective date of the Resale Registration Statement.

Closing and Legal Considerations

The offering is anticipated to close on or about January 12, 2026, subject to customary closing conditions. The new preferred investment options have not been registered under the Securities Act of 1933 and will be offered only under applicable exemptions.

As part of compliance, Arcadia has committed to filing a registration statement with the Securities and Exchange Commission (SEC) to facilitate the resale of common stock associated with the newly issued options.

About Arcadia Biosciences

Founded in 2002, Arcadia Biosciences (Nasdaq: RKDA) focuses on developing high-value wellness products that cater to the increasing consumer demand for healthier choices. With a foundation in agricultural innovation, the company is dedicated to creating next-generation wellness products. For more details, visit www.arcadiabio.com.

Forward-Looking Statements

This announcement contains forward-looking statements in accordance with the Private Securities Litigation Reform Act of 1995. Factors such as completion of the offering, satisfaction of closing conditions, and future organizational funding needs are among the uncertainties that could impact company results.

For a comprehensive understanding of the risks associated with Arcadia Biosciences, including details available in filings made with the SEC, please review their Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Related News